{"id":"NCT00419757","sponsor":"AstraZeneca","briefTitle":"An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma","officialTitle":"A 12-week, Randomised, Double Blind, Active-controlled, Multi-centre, Phase IIIB Study Comparing the Efficacy and Safety of SYMBICORT® pMDI 160/4.5 mg x 2 Actuations Twice Daily Versus Budesonide HFA pMDI 160 mg x 2 Actuations Twice Daily, in Adult/Adolescent (> 12 Yrs) Hispanic Subjects With Asthma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-01","primaryCompletion":"2008-06","completion":"2008-06","firstPosted":"2007-01-09","resultsPosted":"2012-08-27","lastUpdate":"2012-08-27"},"enrollment":558,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"Budesonide/formoterol (SYMBICORT) pMDI","otherNames":[]},{"type":"DRUG","name":"Budesonide HFA pMDI","otherNames":[]}],"arms":[{"label":"Symbicort","type":"ACTIVE_COMPARATOR"},{"label":"Budesonide","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to determine the effectiveness and safety of SYMBICORT® pMDI (a medication approved by the Food and Drug Administration(FDA)) in the Hispanic population.","primaryOutcome":{"measure":"Morning Peak Expiratory Flow (AM PEF)","timeFrame":"Baseline (run-in) and throughout 12 weeks","effectByArm":[{"arm":"Symbicort","deltaMin":25.4,"sd":6},{"arm":"Budesonide","deltaMin":19.9,"sd":6.5}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":39,"countries":["United States","Puerto Rico"]},"refs":{"pmids":["22329608","21875546"],"seeAlso":["http://www.asthmaclinicaltrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":127},"commonTop":["Headache","Viral Upper Respiratory Tract Infection","Cough","Arthralgia","Back Pain"]}}